TRPM8 and prostate cancer: Furthermore, by using the agonist WS12 inside lipid nanocapsules, the authors demonstrate that TRPM8 activation decreases cell migration, and metastasis, suggesting a protective role of the channel on prostate cancer progression (Grolez et al., 2019b; Grolez et al., 2022).